Component-resolved evaluation of the content of major allergens in therapeutic extracts for specific immunotherapy of honeybee venom allergy

ABSTRACT Allergen-specific immunotherapy is the only curative treatment of honeybee venom (HBV) allergy, which is able to protect against further anaphylactic sting reactions. Recent analyses on a molecular level have demonstrated that HBV represents a complex allergen source that contains more relevant major allergens than formerly anticipated. Moreover, allergic patients show very diverse sensitization profiles with the different allergens. HBV-specific immunotherapy is conducted with HBV extracts which are derived from pure venom. The allergen content of these therapeutic extracts might differ due to natural variations of the source material or different down-stream processing strategies of the manufacturers. Since variations of the allergen content of therapeutic HBV extracts might be associated with therapeutic failure, we adressed the component-resolved allergen composition of different therapeutic grade HBV extracts which are approved for immunotherapy in numerous countries. The extracts were analyzed for their content of the major allergens Api m 1, Api m 2, Api m 3, Api m 5 and Api m 10. Using allergen-specific antibodies we were able to demonstrate the underrepresentation of relevant major allergens such as Api m 3, Api m 5 and Api m 10 in particular therapeutic extracts. Taken together, standardization of therapeutic extracts by determination of the total allergenic potency might imply the intrinsic pitfall of losing information about particular major allergens. Moreover, the variable allergen composition of different therapeutic HBV extracts might have an impact on therapy outcome and the clinical management of HBV-allergic patients with specific IgE to particular allergens.

• Publication year

  2017

• Venue

  Human Vaccines & Immunotherapeutics

• Publication date

  2017-05-11

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.1080/21645515.2017.1323603PMID 28494206PMCID 5647995
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Predominant Api m 10 sensitization as risk factor for treatment failure in honey bee venom immunotherapy.

  2016cited by this paper
• rApi m 3 and rApi m 10 improve detection of honey bee sensitization in Hymenoptera venom‐allergic patients with double sensitization to honey bee and yellow jacket venom

  2015cited by this paper
• Anaphylaxis to Insect Venom Allergens: Role of Molecular Diagnostics

  2015cited by this paper
• Hymenoptera Allergens: From Venom to “Venome”

  2014cited by this paper
• Exploring the hidden honeybee (Apis mellifera) venom proteome by integrating a combinatorial peptide ligand library approach with FTMS.

  2014cited by this paper
• Component resolution reveals additional major allergens in patients with honeybee venom allergy.

  2014cited by this paper
• Biochemical and immunological analysis of mould skin prick test solution: current status of standardization

  2013cited by this paper
• Extending the honey bee venome with the antimicrobial peptide apidaecin and a protein resembling wasp antigen 5

  2013cited by this paper
• Clinical Effectiveness of Hymenoptera Venom Immunotherapy: A Prospective Observational Multicenter Study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity

  2013cited by this paper
• Varying Allergen Composition and Content Affects the in vivo Allergenic Activity of Commercial Dermatophagoides pteronyssinus Extracts

  2012cited by this paper
• Honeybee Venom Immunotherapy: A Comparative Study Using Purified and Nonpurified Aqueous Extracts in Patients with Normal Basal Serum Tryptase Concentrations

  2012influential reference
• Added value of IgE detection to rApi m 1 and rVes v 5 in patients with Hymenoptera venom allergy.

  2011cited by this paper
• Api m 10, a genuine A. mellifera venom allergen, is clinically relevant but underrepresented in therapeutic extracts

  2011cited by this paper
• Cultured Human Mast Cells are heterogeneous for expression of the High Affinity IgE Receptor FcεRI

  2011cited by this paper
• Hymenoptera venom immunotherapy.

  2011cited by this paper
• Detection of IgE to recombinant Api m 1 and rVes v 5 is valuable but not sufficient to distinguish bee from wasp venom allergy.

  2011cited by this paper
• Characterization of Phleum pratense pollen extracts by 2‐D DIGE and allergen immunoreactivity

  2010cited by this paper
• Identification, Recombinant Expression, and Characterization of the 100 kDa High Molecular Weight Hymenoptera Venom Allergens Api m 5 and Ves v 3

  2010cited by this paper
• Skin Prick Test Extracts for Dog Allergy Diagnosis Show Considerable Variations Regarding the Content of Major and Minor Dog Allergens

  2010cited by this paper
• Purified vs. nonpurified venom immunotherapy

  2010cited by this paper
• Dissecting cross-reactivity in hymenoptera venom allergy by circumvention of alpha-1,3-core fucosylation.

  2010cited by this paper
• Mast cell diseases and the severity and course of intraoperative anaphylaxis.

  2009cited by this paper
• Molecular composition and biological activity of commercial birch pollen allergen extracts

  2009cited by this paper
• The VISYT trial: Venom Immunotherapy Safety and Tolerability with purified vs nonpurified extracts.

  2009cited by this paper
• Standardization of allergen extracts.

  2008cited by this paper
• Allergen immunotherapy: where is it now?

  2007cited by this paper
• Generation of human monoclonal allergen-specific IgE and IgG antibodies from synthetic antibody libraries.

  2007cited by this paper
• Effect of peak expiratory flow rate measurement on exhaled nitric oxide levels in children with asthma.

  2007cited by this paper
• Insect sting anaphylaxis.

  2007cited by this paper
• Molecular cloning and expression in insect cells of honeybee venom allergen acid phosphatase (Api m 3).

  2006cited by this paper
• Standardization of allergen extracts.

  1978cited by this paper
• INSECT STING ANAPHYLAXIS.

  1963cited by this paper

• „Nicht gereinigte“ Hymenopterengift-Extrakte – vom Protein zum präferierten Produkt

  2026cites this paper
• Impact of natural composed and size excluded Hymenoptera venom preparations on the safety and efficacy of venom immunotherapy: A monocentric experience.

  2025cites this paper
• “Non-purified” Hymenoptera venom extracts—from protein to preferred product

  2025cites this paper
• Clinical features, severity, and immunological changes during venom immunotherapy in children and adults.

  2024cites this paper
• Being Stung Once or Twice by Bees (Apis mellifera L.) Slightly Disturbed the Serum Metabolome of SD Rats to a Similar Extent

  2024cites this paper
• AIT bei Hymenopterengiftallergie im Kindes- und Jugendalter

  2024cites this paper
• Aluminium in dermatology - Inside story of an innocuous metal.

  2024cites this paper
• Cellular and Humoral Response After Induction of Protection and After Finishing Hymenoptera Venom Immunotherapy

  2024cites this paper
• Hymenoptera venom allergy – general data and case discussion

  2024cites this paper
• EAACI Molecular Allergology User's Guide 2.0

  2023cites this paper
• Structural Similarities, in Relation with the Cross-Reactivity, of Hymenoptera Allergenic Dipeptidyl Peptidases IV—An Overall Comparison Including a New Dipeptidyl Peptidase IV Sequence from Vespa velutina

  2023cites this paper
• Allergen-Immuntherapie bei Hymenopterengiftallergie

  2023cites this paper
• Diagnosis and treatment of Hymenoptera venom allergy

  2023cites this paper
• Real-World Safety and Efficacy Clinical Data of an Improved Allergen-Specific Immunotherapy Product for the Treatment of Bee Venom Allergy

  2023influential citation
• Molecular diagnostics and inhibition of cross‐reactive carbohydrate determinants in Hymenoptera venom allergy

  2023cites this paper
• Risikofaktoren bei Bienen- und Wespengiftallergie: aktuelle Bewertung

  2022cites this paper
• Diagnosis and Management of Insect Allergy: Barriers and Facilitators in the United States

  2022cites this paper
• Molecular determination of insect venom allergies

  2022cites this paper
• Diagnosis of Hymenoptera Venom Allergy: State of the Art, Challenges, and Perspectives

  2022cites this paper
• Major Allergen Content In Allergen Immunotherapy Products: The Limited Value of Numbers.

  2022cites this paper
• Anaphylactic reactions in the build-up phase of rush immunotherapy for bee venom allergy in pediatric patients: a single-center experience

  2022cites this paper
• Allergen Content of Therapeutic Preparations for Allergen-Specific Immunotherapy of European Paper Wasp Venom Allergy

  2022cites this paper
• Component-Resolved Evaluation of the Risk and Success of Immunotherapy in Bee Venom Allergic Patients

  2022cites this paper
• Precision medicine in the allergy clinic: the application of component resolved diagnosis

  2022cites this paper
• Hymenoptera venom immunotherapy without human serum albumin as a stabilizer in a canine patient

  2021cites this paper
• Bedeutung der molekularen Diagnostik für die Allergenimmuntherapie

  2021cites this paper
• Risk factors in bee and Vespula venom allergy: state of the art

  2021cites this paper
• Venom Immunotherapy: From Proteins to Product to Patient Protection

  2021influential citation
• Immunotherapy for Hymenoptera venom allergy compared with real‐life stings: Are we doing our best?

  2020cites this paper
• Precision Medicine in Hymenoptera Venom Allergy: Diagnostics, Biomarkers, and Therapy of Different Endotypes and Phenotypes

  2020cites this paper
• Api m 6 and Api m 10 as Major Allergens in Patients with Honeybee Venom Allergy.

  2020cites this paper
• The Honeybee Venom Major Allergen Api m 10 (Icarapin) and Its Role in Diagnostics and Treatment of Hymenoptera Venom Allergy

  2020cites this paper
• Current challenges in molecular diagnostics of insect venom allergy

  2020cites this paper
• Venom immunotherapy in Europe and the United States

  2020cites this paper
• A WAO — ARIA — GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020

  2020cites this paper
• Current challenges in molecular diagnostics of insect venom allergy

  2020cites this paper
• Venom immunotherapy in Europe and the United States

  2020cites this paper
• Successful adaptation of bee venom immunotherapy for a monosensitized patient to Api m 10.

  2020cites this paper
• The honey bee venom allergen Api m 10 displays one major IgE epitope, Api m 10160‐174

  2020cites this paper
• ANTIVIRAL EFFECT OF THE EGYPTIAN BEE VENOM (BV) AND ITS FRACTION (PLA2) ON INFLUENZA VIRUS: IN-VITRO STUDY

  2020cites this paper
• Marker allergens in Hymenoptera venom allergy — Characteristics and potential use in precision medicine

  2020cites this paper
• Study of Human IgG and IgE Antibodies Against Bee (Apis mellifera) Venom

  2020cites this paper
• The Use of Molecular Allergy Diagnosis in Anaphylaxis: a Literature Review

  2019cites this paper
• Beekeepers

  2019cites this paper
• The role of component-resolved diagnosis in Hymenoptera venom allergy.

  2019cites this paper
• Lessons from times of shortage: Interchangeability of venom preparations and dosing protocols

  2019cites this paper
• Worldwide perspectives on venom allergy

  2019cites this paper
• Clinical outcomes related to molecular allergy diagnosis

  2019cites this paper
• Characterization of the honeybee venom proteins C1q‐like protein and PVF1 and their allergenic potential

  2018cites this paper
• Component‐resolved diagnostics to direct in venom immunotherapy: Important steps towards precision medicine

  2018cites this paper
• The high molecular weight dipeptidyl peptidase IV Pol d 3 is a major allergen of Polistes dominula venom

  2018cites this paper
• Improved Diagnosis and Therapy of Hymenoptera Venom Allergy by Component-Resolved Approaches

  2018cites this paper
• Biopanning of allergens from wasp sting patients

  2018cites this paper
• Venom immunotherapy in patients with allergic reactions to insect stings

  2018cites this paper
• Bienengift-SIT: individualisierte Präparateauswahl

  2017cites this paper
• Component resolved diagnostics for hymenoptera venom allergy

  2017cites this paper
• Broad perspectives of allergen specific immunotherapy

  2017cites this paper
• Bienengift-SIT: individualisierte Präparateauswahl

  2017cites this paper